- Active, not recruiting
NCT00572169: UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy.
Updated: Apr 25, 2022
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy. With this study - Total Therapy IIIB - researchers are extending the findings of Total Therapy III based what they have learned from the first two studies (Total Therapy I and II), with new research strategies designed to explore why chromosome abnormalities found in persons with multiple myeloma affect the outcome of drug therapy used in this disease."
Locations
United States, Arkansas
University of Arkansas for Medical Sciences/Myeloma Institute
ClinicalTrials.gov Identifier: NCT00572169
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy - A Phase II Study Incorporating Bone Marrow Microenvironment (ME) - Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DTPACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance
First Posted : December 12, 2007
clinicaltrials.gov/ct2/show/NCT00572169
VDTPACE =